Scientists have found that glucose plays a significant role in how the brain functions.

Published Date: 26 Apr 2023

Nearly a quarter of the body's sugar energy, or glucose, is consumed daily by the human brain, which also has a sweet tooth. Now, scientists from the Gladstone Institutes and UC San Francisco (UCSF) have provided fresh insight into how.

Read Full News

Latest News

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

GLP-1 RAs Linked to Lower Diabetes, CV Risk than Metformin in Prediabetes

TRANSCEND-T2D-2: Retatrutide Beats Semaglutide 2 mg on A1C, Weight Loss

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

4 Endocrinology Headlines You Missed in August 2026 Chelsie Derman

New approval for tirzepatide, phase 3 wins for avexitide and retatrutide, and a GLP-1 telehealth safety gap in August's biggest endocrinology stories.

Todays Updates

Episode 179: Cognitive Changes in Multiple Sclerosis: Rethinking Processing Speed and Memory James F. Sumowski, PhD, Isabella Ciccone, MPH

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]

Early ACHIEVE Findings Move Z-Basivarsen Toward Phase 3 in Myotonic Dystrophy Type 1 Marco Meglio, Laurie Gutmann, MD

Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).

Treating Depression in CKD After CONCORD, With Susan Hedayati, MD, MHSc Susan Hedayati, MD, MHSc

Hedayati recommends shared decision making and a 4 to 6 week treatment trial, stopping therapy when patients don’t respond.

Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD Oriol Bestard, MD, PhD

PAES data from ASN Kidney Week 2026 show graft, patient, and kidney function outcomes at 1 year in crossmatch-positive transplants.

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

Todays Updates

Episode 179: Cognitive Changes in Multiple Sclerosis: Rethinking Processing Speed and Memory James F. Sumowski, PhD, Isabella Ciccone, MPH

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]

Early ACHIEVE Findings Move Z-Basivarsen Toward Phase 3 in Myotonic Dystrophy Type 1 Marco Meglio, Laurie Gutmann, MD

Treating Depression in CKD After CONCORD, With Susan Hedayati, MD, MHSc Susan Hedayati, MD, MHSc

Hedayati recommends shared decision making and a 4 to 6 week treatment trial, stopping therapy when patients don’t respond.

Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD Oriol Bestard, MD, PhD

PAES data from ASN Kidney Week 2026 show graft, patient, and kidney function outcomes at 1 year in crossmatch-positive transplants.

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

Latest News

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

GLP-1 RAs Linked to Lower Diabetes, CV Risk than Metformin in Prediabetes

TRANSCEND-T2D-2: Retatrutide Beats Semaglutide 2 mg on A1C, Weight Loss

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

HTTP error: 503

News All Time

EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes

Retatrutide Improves Weight Loss, Knee Osteoarthritis Pain, Sleep Apnea Versus Placebo

Q4 2026 Preview: 7 FDA Decisions to Watch

Semaglutide 2 mg Escalation Tied to Lower MACE vs Tirzepatide Switch in T2D

REMAIN-1: Improved GLP-1-Induced Weight Loss Retention With Revita DMR System Ryan Livingston

New data from the 45-patient Midpoint Cohort, despite not being powered for statistical significance, indicate a potentially substantial benefit.

FDA Accepts NDA for Encaleret for Autosomal Dominant Hypocalcemia Type 1 Ryan Livingston

If approved, encaleret will be the first treatment specifically indicated for this underrepresented patient population.

HTTP error: 503HTTP error: 503

FDA Accepts Resubmitted CAM2029 NDA for Acromegaly Ryan Livingston

FDA accepted Camurus’ resubmitted CAM2029 application for acromegaly, with a target action date of December 18, 2026.

5 Endocrinology Headlines You Missed in July 2026 Ryan Livingston

New Drug Applications and key trial readouts punctuated July for endocrinology, with treatments for hypocalcemia, diabetes, and more.

Continuous Glucose Monitoring in Type 2 Diabetes, With John Anderson, MD John Anderson, MD

Anderson discusses recent advancements in CGM technology, as well as the myriad behavioral and clinical benefits of CGM use in T2D with or without insulin.

Retatrutide Meets Phase 3 Weight-Loss Endpoints in 2 Obesity Trials Ryan Livingston

Retatrutide met 80-week weight-loss endpoints in TRIUMPH-2 and TRIUMPH-3, prompting a planned FDA submission in Q1 2027.

HTTP error: 503

500,000 Patients With Diabetes May Lose Healthcare Under New Medicaid Legislation Ryan Livingston

Limits to provider taxes used to fund Medicaid programs, as well as increased eligibility requirements and cost-sharing obligations, may make insurance inaccessible.

Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3 Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline data from the TRIUMPH-3 trial of retatrutide.

Ascendis Reports 78-Week Data From COACH Trial for Achondroplasia Ryan Livingston

Combination therapy with navepegritide and lonapegsomatropin has demonstrated its efficacy in improving mean annualized growth velocity in pediatric patients.

Scientists have found that glucose plays a significant role in how the brain functions.

Latest News

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

GLP-1 RAs Linked to Lower Diabetes, CV Risk than Metformin in Prediabetes

TRANSCEND-T2D-2: Retatrutide Beats Semaglutide 2 mg on A1C, Weight Loss

Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

4 Endocrinology Headlines You Missed in August 2026 Chelsie Derman

Todays Updates

Episode 179: Cognitive Changes in Multiple Sclerosis: Rethinking Processing Speed and Memory James F. Sumowski, PhD, Isabella Ciccone, MPH

Early ACHIEVE Findings Move Z-Basivarsen Toward Phase 3 in Myotonic Dystrophy Type 1 Marco Meglio, Laurie Gutmann, MD

Treating Depression in CKD After CONCORD, With Susan Hedayati, MD, MHSc Susan Hedayati, MD, MHSc

Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD Oriol Bestard, MD, PhD

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

Todays Updates

Episode 179: Cognitive Changes in Multiple Sclerosis: Rethinking Processing Speed and Memory James F. Sumowski, PhD, Isabella Ciccone, MPH

Early ACHIEVE Findings Move Z-Basivarsen Toward Phase 3 in Myotonic Dystrophy Type 1 Marco Meglio, Laurie Gutmann, MD

Treating Depression in CKD After CONCORD, With Susan Hedayati, MD, MHSc Susan Hedayati, MD, MHSc

Imlifidase Opens a Transplant Window, With Oriol Bestard, MD, PhD Oriol Bestard, MD, PhD

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

Latest News

News All Time

EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes

Retatrutide Improves Weight Loss, Knee Osteoarthritis Pain, Sleep Apnea Versus Placebo

Q4 2026 Preview: 7 FDA Decisions to Watch

Semaglutide 2 mg Escalation Tied to Lower MACE vs Tirzepatide Switch in T2D

REMAIN-1: Improved GLP-1-Induced Weight Loss Retention With Revita DMR System Ryan Livingston

FDA Accepts NDA for Encaleret for Autosomal Dominant Hypocalcemia Type 1 Ryan Livingston

FDA Accepts Resubmitted CAM2029 NDA for Acromegaly Ryan Livingston

5 Endocrinology Headlines You Missed in July 2026 Ryan Livingston

Continuous Glucose Monitoring in Type 2 Diabetes, With John Anderson, MD John Anderson, MD

Retatrutide Meets Phase 3 Weight-Loss Endpoints in 2 Obesity Trials Ryan Livingston

500,000 Patients With Diabetes May Lose Healthcare Under New Medicaid Legislation Ryan Livingston

Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3 Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

Ascendis Reports 78-Week Data From COACH Trial for Achondroplasia Ryan Livingston

Recommended News For You

Recommended Articles For You

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.